<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bakris, George L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Potential Blood Pressure Lowering Benefit of Azilsartan Medoxomil</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses findings from this phase III, multicenter, parallel-group, double-blind, randomized placebo-and active-controlled trial [NCT00696241]. The purpose of this study was to compare the BP lowering effects of azilsartan medoxomil with olmesartan medoxomil and placebo over a period of 6 weeks in patients with primary hypertension.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>